Market Overview

According to fortune business insights, the global hemato oncology testing market size was valued at USD 4.54 billion in 2025. The market is projected to grow from USD 4.84 billion in 2026 to USD 8.45 billion by 2034, exhibiting a CAGR of 7.2% during the forecast period. North America dominated the global hemato oncology testing market with a market share of 40.96% in 2025.

The analysis shows that growth is driven by the rising prevalence of blood disorders and the increasing adoption of advanced and easier-to-run tests for detection. For instance, the National Institutes of Health estimated 66,890 new cases of leukemia were expected in the U.S. in 2025. This trend, coupled with a growing emphasis on preventive care and screening, indicates a strong and rising demand for hemato oncology testing worldwide.

Major Players Profiled in the Market Report:

• F. Hoffmann-La Roche AG (Switzerland)
• Abbott (U.S.)
• Danaher Corporation (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Agilent Technologies, Inc. (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• Sysmex Corporation (Japan)
• Illumina, Inc. (U.S.)
• QIAGEN N.V. (Netherlands)
• BD (U.S.)
• Invivoscribe, Inc. (U.S.)
• Invitae Corporation (U.S.)

Segments

High Test Volume to Drive Assay Kits & Reagents Segment Growth
Based on products & services, the market is divided into assay kits & reagents, services, and instruments & platforms. The assay kits & reagents segment holds the largest market share due to high test volumes, repetitive purchases, and growing awareness, which are further boosted by new product introductions.

Higher Prevalence to Drive Lymphoma Segment Growth
By cancer type, the market is categorized into leukemia, lymphoma, multiple myeloma, and others. The lymphoma segment leads the market as it includes numerous subtypes that require precise classification to guide effective treatment decisions, driving the demand for focused diagnostic tools.

Technological Advancements to Drive Molecular Diagnostics Segment Growth
Based on testing technology, the market is segmented into flow cytometry, fluorescence in situ hybridization, molecular diagnostics, immunohistochemistry, and others. The molecular diagnostics segment holds the largest market share, driven by its ability to provide specific disease information that is crucial for making therapy decisions and monitoring patients.

Higher Testing Volumes to Drive Hospitals & Diagnostic Laboratories Segment Growth
Based on end-user, the market is segmented into academic & research institutes, hospitals & diagnostic laboratories, and others. The hospitals & diagnostic laboratories segment dominates the market as these facilities are the primary points for patient testing and treatment decision-making, processing high volumes of samples.

Geographically, the market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

For detailed market insights: https://www.fortunebusinessinsights.com/hemato-oncology-testing-market-115278

Report Coverage

The report offers:

• Major growth drivers, restraining factors, opportunities, and potential challenges for the market.
• Comprehensive insights into regional developments.
• List of major industry players.
• Key strategies adopted by the market players.
• The latest industry developments include product launches, partnerships, mergers, and acquisitions.

Drivers & Restraints

Growing Demand for Personalized Cancer Treatment to Propel Market Growth
The rapid growth in demand for personalized cancer therapies is boosting the market. Healthcare professionals are increasingly focused on using targeted tests to deliver accurate diagnoses and tailored treatments, which improves patient outcomes. This creates a steady need for tests that can confirm cancer types and monitor disease signals over time.

However, the considerable cost of advanced hemato oncology tests, coupled with irregular and unclear reimbursement policies, may hamper market growth. These financial barriers can limit the adoption of new tests in hospitals and smaller labs.

Regional Insights

Rising Prevalence of Blood Cancer in the U.S. Propels Market Growth in North America
North America holds the dominant hemato oncology testing market share, valued at USD 1.86 billion in 2025. The region’s growth is attributed to the rising prevalence of blood cancer, an increasing number of advanced product launches, strong healthcare infrastructure, and high technological adoption.

Asia Pacific is one of the fastest-growing regions in the market. The growth is attributed to the increasing demand for blood cancer diagnostics in developing nations, particularly China and India.

Hemato Oncology Testing Market Future Growth:

The hemato oncology testing market is experiencing robust growth fueled by the rising adoption of molecular diagnostics for screening blood cancer. This trend is driven by the launch of new, more accessible panels and assays that offer higher accuracy and shorter turnaround times. Furthermore, the increasing demand for advanced screening tests in hospitals and diagnostic labs, along with strategic partnerships to expand in-house testing capabilities, is creating significant opportunities for market expansion.

Competitive Landscape

Focus on New Product Introduction by Key Players to Propel Market Progress
The market is semi-consolidated, with key players such as F. Hoffmann-La Roche AG, Abbott, and Danaher Corporation holding a significant share. These companies maintain their leadership through strategic activities, including collaborations to advance research and a strong focus on launching new products with advanced technologies. Other prominent players are also prioritizing new product launches and partnerships to expand their global market presence.

Key Industry Development

• October 2025: Flatiron Health announced the launch of new AI-powered hematology datasets to accelerate clinical trials and the assessment of treatment outcomes.
• May 2025: Labcorp announced an expansion of its oncology portfolio to boost advanced research and cancer care.